| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-645
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
1999-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2002-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2002506833-A |
| titleOfInvention |
Carrier for in vivo delivery of therapeutic agents |
| abstract |
(57) [Summary]nProvided is a carrier for in vivo delivery of a therapeutic agent containing a thiol group, which is conjugated to the carrier via a biodegradable disulfide bond. Although the extracellular fluid in vivo does not provide a suitable environment to effectively reduce disulfide bonds, the cytosol of the cell provides a suitable environment so that the therapeutic agent remains in the body until the carrier crosses the cell membrane. During circulation, it will remain substantially associated with the carrier. As a result, the therapeutic is protected from degradation and renal clearance, limiting the potential of the therapeutic to elicit an immune response. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010536986-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006516295-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101090784-B1 |
| priorityDate |
1998-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |